{"id":"ilx651","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":{"chemblId":"CHEMBL2107376","moleculeType":"Protein","molecularWeight":"643.31"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ILX651 works by inhibiting the sodium-iodide symporter (NIS), a protein responsible for the uptake of iodine in thyroid cells. This inhibition can lead to a reduction in iodine uptake and potentially reduce the growth of thyroid cancer cells.","oneSentence":"ILX651 is a small molecule inhibitor of the sodium-iodide symporter (NIS) with potential use in thyroid cancer treatment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:35:25.097Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thyroid cancer"}]},"trialDetails":[{"nctId":"NCT00078455","phase":"PHASE2","title":"Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2003-12","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":""},{"nctId":"NCT00082134","phase":"PHASE2","title":"Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"","conditions":"Hormone-refractory Prostate Cancer","enrollment":40},{"nctId":"NCT00068211","phase":"PHASE2","title":"Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2003-08","conditions":"Melanoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ILX651","genericName":"ILX651","companyName":"Genzyme, a Sanofi Company","companyId":"genzyme-a-sanofi-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ILX651 is a small molecule inhibitor of the sodium-iodide symporter (NIS) with potential use in thyroid cancer treatment. Used for Thyroid cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}